Travere Therapeutics, Inc., an integrated biopharmaceutical company, focuses on identifying, developing, and delivering therapies to people living with rare kidney and metabolic diseases.

Its approved products include FILSPARI (sparsentan), a once-daily, oral medication is designed to target two critical pathways (endothelin 1 and angiotensin-II) in the disease progression of IgA; and Thiola and Thiola EC (tiopronin tablets) for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.

The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria.

It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome.

The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020.

Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.